Laurus Labs Limited Cash Flow Conversion Efficiency
Laurus Labs Limited cash flow conversion efficiency. Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has a cash flow conversion efficiency ratio of 0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs10.93 Billion ≈ $118.22 Million USD) by net assets (Rs49.34 Billion ≈ $533.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Laurus Labs Limited (2013–2026)
Cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2026. This chart illustrates how Laurus Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Laurus Labs Limited share price for real-time trading data and today's change.
Laurus Labs Limited Cash Flow Conversion Ratio Explained
Laurus Labs Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Laurus Labs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Laurus Labs Limited ranked by their cash flow conversion efficiency. Also see market cap of Laurus Labs Limited for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lamar Advertising Company
NASDAQ:LAMR
|
0.279x |
|
GD Power Development Co Ltd
SHG:600795
|
0.121x |
|
iA Financial Corporation Inc
TO:IAG
|
0.026x |
|
RPM International Inc
NYSE:RPM
|
0.073x |
|
SOUTH32 Ltd
AU:S32
|
0.060x |
|
Rede D'Or São Luiz S.A.
SA:RDOR3
|
-0.078x |
|
SK Telecom Co Ltd ADR
NYSE:SKM
|
0.086x |
|
Bank of Baroda
NSE:BANKBARODA
|
-0.146x |
Annual Cash Flow Conversion Efficiency for Laurus Labs Limited (2013–2026)
The table below shows the annual cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2026. Review how much free cash does Laurus Labs Limited generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs54.31 Billion ≈ $587.38 Million |
Rs14.59 Billion ≈ $157.83 Million |
0.269x | +105.55% |
| 2025-03-31 | Rs46.03 Billion ≈ $497.75 Million |
Rs6.02 Billion ≈ $65.07 Million |
0.131x | -19.18% |
| 2024-03-31 | Rs41.16 Billion ≈ $445.08 Million |
Rs6.66 Billion ≈ $71.99 Million |
0.162x | -34.11% |
| 2023-03-31 | Rs40.49 Billion ≈ $437.85 Million |
Rs9.94 Billion ≈ $107.49 Million |
0.245x | -9.49% |
| 2022-03-31 | Rs33.59 Billion ≈ $363.27 Million |
Rs9.11 Billion ≈ $98.53 Million |
0.271x | -3.76% |
| 2021-03-31 | Rs26.01 Billion ≈ $281.26 Million |
Rs7.33 Billion ≈ $79.27 Million |
0.282x | +43.58% |
| 2020-03-31 | Rs17.70 Billion ≈ $191.39 Million |
Rs3.47 Billion ≈ $37.57 Million |
0.196x | +2.77% |
| 2019-03-31 | Rs15.58 Billion ≈ $168.54 Million |
Rs2.98 Billion ≈ $32.19 Million |
0.191x | -17.32% |
| 2018-03-31 | Rs14.83 Billion ≈ $160.34 Million |
Rs3.42 Billion ≈ $37.04 Million |
0.231x | -7.42% |
| 2017-03-31 | Rs13.30 Billion ≈ $143.88 Million |
Rs3.32 Billion ≈ $35.90 Million |
0.250x | +9.96% |
| 2016-03-31 | Rs8.52 Billion ≈ $92.12 Million |
Rs1.93 Billion ≈ $20.90 Million |
0.227x | +352.81% |
| 2015-03-31 | Rs7.21 Billion ≈ $77.96 Million |
Rs-647.06 Million ≈ $-7.00 Million |
-0.090x | -126.54% |
| 2014-03-31 | Rs3.58 Billion ≈ $38.76 Million |
Rs1.21 Billion ≈ $13.11 Million |
0.338x | -0.57% |
| 2013-03-31 | Rs2.59 Billion ≈ $28.04 Million |
Rs882.08 Million ≈ $9.54 Million |
0.340x | -- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal… Read more